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Abstract Previously, we have shown that translation eukaryotic
initiation factor (eIF) 4GI is cleaved during anti-Fas-mediated
apoptosis. Here, we have investigated the effects of the
proteasome inhibitors, MG132 and lactacystin, and the im-
munosuppressants, 2-amino-2[2-(4-octylphenyl)ethyl]-1,3,pro-
pane diol (FTY720) and cyclosporin A, on the integrity of
eIF4GI and eIF4GII in T cells. Using wild-type Jurkat T cells,
we show that the proteasome inhibitors MG132 and lactacystin
promote the cleavage of eIF4G, activate caspase-8 and caspase-
3-like activities and decrease cell viability. Furthermore, MG132
also promotes the cleavage of eIF4G and the activation of
caspase-3-like activity in a caspase-8-deficient Jurkat cell line
which is resistant to anti-Fas-mediated apoptosis. Using specific
anti-peptide antisera, we show that both eIF4GI and eIF4GII are
cleaved in either cell line in response to MG132 and lactacystin.
In response to such treatments, we demonstrate that the
fragments of eIF4GI generated include those previously observed
with anti-Fas antiserum together with a novel product which
lacks the ability to interact with eIF4E. In contrast, cells treated
with the immunosuppressants FTY720 and cyclosporin A appear
to contain only the novel cleavage fragment of eIF4GI and to
lack those characteristic of cells treated with anti-Fas antiserum.
These data suggest that caspase-8 activation is not required for
apoptosis and eIF4G cleavage mediated by proteasome inhibitors
and immunosuppressants in human T cells. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Translation eukaryotic initiation factor (eIF) 4G, which
exists in two forms (eIF4GI and eIF4GII), plays an pivotal
role in the mechanism of translation by acting as a molecular
bridge between other components of the ribosomal initiation
complex (reviewed in [1^3]). In vivo, eIF4G exists partly in the
form of a complex with the mRNA cap-binding protein eIF4E
and the ATP-dependent RNA helicase eIF4A, constituting
eIF4F (reviewed in [2^5]). Within the sequence of eIF4G,
there are domains that interact with eIF4E [5^7], eIF4A
[8^12], eIF3 [9,10,12], the poly(A)-binding protein (PABP;
[13^16]) and the eIF4E kinase, Mnk1 [2,3,10,17]. Interaction
of PABP with eIF4G has been suggested to facilitate the func-
tional association of the 3P end of an mRNA with the 5P end
[18], with the association of eIF4G with eIF4E markedly en-
hancing the binding of the latter to the mRNA cap [2,3,19].
Previously, it has been reported that induction of apoptosis
in lymphocytes [20^23] or HeLa cells [24] results in an inhibi-
tion of overall protein synthesis and the selective cleavage of
translation eIF4GI [20^22,25] and eIF4GII [26,27]. While cas-
pase-8 activity is required for proteolysis of eIF4G in response
to treatment of cells with anti-Fas antiserum [21], caspase-3
activity is both necessary and su⁄cient for the cleavage of
eIF4G in vivo and in vitro [27,28]. Although anti-Fas treat-
ment promoted a caspase-8-dependent increase in the activity
of the p38 MAP kinase and JNK stress kinases [21,29], inhib-
itor studies showed that cleavage of eIF4G did not require
signalling through the p38 MAP kinase pathway [20].
In addition to Fas/CD95 receptor activation, apoptosis can
also be promoted in T cells by inhibition of proteasome ac-
tivity or treatment of cells with immunosuppressive drugs.
The proteasome is a multicatalytic proteinase complex respon-
sible for intracellular protein degradation in mammalian cells
[30]. Inhibition of the 26S proteasome with MG132 (N-carbo-
benzoxyl-Leu-Leu-Leucinal) or lactacystin has been reported
to induce activation of stress kinases and programmed cell
death in a number of cell types [31^36]. These responses are
also activated following treatment of cells with immunosup-
pressants such as 2-amino-2[2-(4-octylphenyl)ethyl]-1,3,pro-
pane diol (FTY720) and cyclosporin A (CsA; [37^41]). In
vivo, consistent with its role as an immunosuppressant [42],
FTY720 induces a drastic decrease in the level of T lympho-
cytes in the blood [40], possibly mediated by its direct e¡ect
on the inhibition of mitochondrial function resulting from
cytochrome c release [41].
Here, we have investigated the e¡ects of MG132, lactacys-
tin, FTY720 and CsA on the integrity of eIF4GI and eIF4GII
in T lymphocytes. We show that these agents induce the acti-
vation of caspase-like activities and the cleavage of eIF4G
into discrete, novel fragments. This also occurs in caspase-8-
de¢cient Jurkat T cells, which are resistant to anti-Fas-in-
duced apoptosis. The proteolysis of both eIF4GI and eIF4GII
is associated with a decrease in cell viability and the inhibition
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of protein synthesis in both cell types. These data suggest that
eIF4G cleavage mediated by proteasome inhibitors and im-
munosuppressants in human T cells can be promoted by the
activation of caspase-8-dependent and -independent path-
ways.
2. Materials and methods
2.1. Chemicals and biochemicals
Materials for tissue culture were from Gibco Life Technologies and
anti-Fas antiserum (clone CH-11) was from Upstate Biotechnology.
FTY720 and CsA were kind gifts from Dr. J. Kay (Sussex, UK) and
Dr. S. Matsuda (Yoshitoma Pharmaceutical Industries, Tokyo),
zVAD.fmk was from Alexis Corporation, Immobilon polyvinylidine
di£uoride (PVDF) was from Millipore, MG132, N-acetyl-Leu-Leu-
Nle-CHO (ALLN; MG101) and synthetic lactacystin were from Cal-
biochem. Antiserum speci¢c to the C-terminus of eIF4GII was a gift
from Dr. N. Sonenberg (Montreal, QC, Canada) and unless otherwise
stated, all other chemicals were from Sigma.
2.2. Tissue culture
Wild-type human Jurkat T cells and a caspase-8-de¢cient Jurkat
subclone (provided by Dr. J. Blenis, Harvard Medical School, Cam-
bridge, CA, USA) were cultured in RPMI 1640 supplemented with
10% foetal calf serum, as described [21,29].
2.3. Treatment of cells
Cells (5U106 cells in 5 ml) were isolated by centrifugation, washed
in ice-cold phosphate-bu¡ered saline (PBS) and resuspended in 1 ml
of RPMI 1640. Where indicated, cells were incubated on ice for 30 min
with or without 250 ng/ml anti-Fas antiserum [43], FTY720, MG132
or CsA at the doses and for the times indicated in the individual ¢gure
legends. Cells were isolated by centrifugation, washed in ice-cold PBS
and resuspended in 5 ml of original culture medium in the absence of
these agents for the times indicated in the individual ¢gure legends.
When used, zVAD.fmk (50 WM) or ALLN (10 Wg/ml) were added to
cultures for 60 min prior to isolation of the cells, and were present in
all subsequent incubations.
2.4. Preparation of cell extracts
Following treatment, cells were isolated in a cooled centrifuge and
washed with 1 ml PBS containing 40 mM L-glycerophosphate and
2 mM benzamidine. Pellets (5U106 cells) were resuspended in 100 Wl
ice-cold bu¡er A (50 mM 3-[N-morpholino] propanesulphonic acid
(MOPS)^KOH, pH 7.2, 2.5 mM ethylene glycol-bis(L-aminoethyl
ether) (EGTA), 1 mM EDTA, 40 mM sodium £uoride, 1 WM micro-
cystin, 80 mM NaCl, 7 mM 2-mercaptoethanol, 2 mM benzamidine,
1 mM phenylmethylsulphonyl £uoride (PMSF), 2 mM Na3VO4) and
lysed by the addition of 0.5% (by vol.) Igepal and vortexing. Cell
debris was removed by centrifugation in a microfuge for 5 min at
4‡C and the resultant supernatants frozen in liquid N2.
2.5. Measurement of AC-DEVD-AMC and AC-IETD-AMC cleaving
caspase activity
Following treatment, cell extracts were prepared in bu¡er B (10
mM Tris^HCl, pH 8, 130 mM NaCl, 2 mM EDTA, 10 mM sodium
pyrophosphate, 1% (v/v) Triton X-100, 1 mM PMSF, 0.25 Wg/ml
pepstatin A) and adjusted to equal protein concentration. The £uo-
rogenic caspase substrates AC-DEVD-AMC or AC-IETD-AMC
(20 WM; Biosource International, UK) were added and £uorescence
was determined at 60 min intervals following excitation at 380 nm and
reading at 440 nm using a SpectraMax (Molecular Devices, USA).
2.6. SDS^PAGE and immunoblotting
Samples containing equal amounts of protein were resolved by
SDS^PAGE and processed, as described previously [21,44,45]. Anti-
sera speci¢c for the middle or C-terminal domains of eIF4GI were as
described previously [26], and antiserum to the C-terminus of eIF4GII
was as described previously [7,27].
2.7. Isolation of eIF4E and associated factors by 7-methyl guanosine
triphosphate (m7GTP)-Sepharose chromatography
eIF4E and associated proteins were isolated by m7GTP-Sepharose
chromatography, as described previously [21,45^47], and the associ-
ated eIF4GI was visualised by immunoblotting.
3. Results
3.1. The proteasome inhibitors, MG132 and lactacystin
promote cleavage of eIF4GI and eIF4GII by a
caspase-8-independent mechanism
Inhibition of the 26S proteasome induces activation of
stress kinases, promotes apoptosis [31^36] and potentiates
the cleavage of eIF4GI in Jurkat cells treated with anti-Fas
antiserum [20,22]. To determine whether proteasome inhibi-
tors alone in£uence the integrity of eIF4GI, wild-type Jurkat
T cells and caspase-8 mutant cells, which are resistant to anti-
Fas-mediated apoptosis, were incubated for various times
with MG132. Fig. 1A (upper panel) shows that a decrease
in cell viability was evident in both cell lines within 8 h fol-
lowing treatment of cells with MG132. To examine whether
caspase processing is involved in cell death mediated by pro-
teasome inhibitors, we have monitored caspase-8 and caspase-
3-like protease activities at 8 h of treatment with MG132
using £uorogenic substrates. Fig. 1B shows that as with
anti-Fas activation, MG132 promotes the activation of cas-
pase-3 and caspase-8-like activities in wild-type Jurkat cells,
involving a process which is sensitive to the general caspase
inhibitor, zVAD.fmk. These results are consistent with the
¢nding that MG132 can activate a number of caspases in
glioma cell lines [36]. In contrast, treatment of caspase-8 mu-
tant cells with MG132 only leads to the activation of caspase-
3-like activity. As predicted from earlier studies [21,29], cas-
pase-8 and caspase-3-like activities are not increased in re-
sponse to anti-Fas treatment in the mutant cell line (Fig.
1B). The integrity of eIF4GI in these extracts was visualised
by immunoblotting. Fig. 1C (lanes 1^4) shows that treatment
of cells with MG132 for 8 h also promotes the cleavage of
PARP and the partial cleavage of eIF4GI with similar kinetics
in both the wild-type and caspase-8 mutant cells. In addition
to the partial cleavage of eIF4GI, eIF2K phosphorylation lev-
els increase by two-fold at 8 h, and protein synthesis rates
decrease to 30% of control levels (data not shown). In addi-
tion, the loss of integrity of eIF4GI in response to MG132 in
caspase-8 mutant cells is prevented by pre-treatment of cells
with zVAD.fmk (Fig. 1C, lane 5 vs. 6), indicating a role for
caspase-like activity downstream of caspase-8 in their gener-
ation. However, to e¡ect total cleavage of eIF4GI, these cell
lines require treatment with 2.5^10 Wg/ml MG132 for 20 h,
resulting in a decrease in cell viability to less than 50% (Fig.
1D). Similar cytotoxic e¡ects of 0.5^2.5 Wg/ml MG132 over 24
h have been reported for glioma cell lines [36]. At concentra-
tions of MG132 greater than 2.5 Wg/ml, eIF4GI is e⁄ciently
cleaved into stable, discrete immunoreactive fragments in both
wild-type (Fig. 1B; Fig. 2A, lanes 2 and 8 vs. lanes 1 and 7)
and caspase-8 mutant cell lines (Fig. 1B; Fig. 2A, lanes 5 and
11 vs. lanes 4 and 10). Therefore, our studies show that
MG132 promotes cell death and the cleavage of eIF4GI in
Jurkat cells via caspase-8-dependent and -independent path-
ways.
Inhibition of 20S proteasome activity with 20 WM synthetic
lactacystin in either wild-type (Fig. 2A, lanes 3 and 9) or
caspase-8 mutant cells (lanes 6 and 12) also results in the
cleavage of eIF4GI, the appearance of M-FAG and C-FAG
([25] ; Fig. 2B), and a moderate increase in the novel 50 kDa
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fragment, M1. Treatment of cells with a combination of
MG132 and lactacystin did not appreciably accelerate these
events, suggesting that both reagents are working via similar
pathways in Jurkat cells (data not shown). Throughout this
study, a low, variable level of the M1 cleavage fragment was
present in control extracts from both Jurkat cell lines (see also
Figs. 1C and 4A), possibly re£ecting the presence of low levels
of apoptotic cells in each population [29,48]. This 50 kDa
fragment (M1) is recognised by antiserum speci¢c to the cen-
tral region of eIF4G (antiserum W; Fig. 2, lanes 1^6), but not
by antiserum speci¢c to the N-terminus (antiserum B; data
not shown) or by antiserum to the C-terminus (antiserum E;
Fig. 2, lanes 7^12), indicating that it is derived from the cen-
tral region of eIF4GI (see also Fig. 3C). Use of anti-peptide
antisera indicated that the other fragments generated follow-
ing treatment of cells with lactacystin are similar to those
observed with MG132 (Fig. 2A, lanes 2, 5, 8, 11). M-FAG
and C-FAG resemble the fragments of eIF4GI generated ex-
clusively in wild-type cells during anti-Fas-mediated apoptosis
[21], only being visualised by antiserum W or antiserum E,
respectively (Fig. 2A). These data suggest that inhibition of
proteasome activity generates M-FAG, C-FAG and the novel
fragment of eIF4GI, M1, through activation of caspase-like
activity downstream of caspase-8.
Another explanation is that the M1 fragment is derived
from eIF4GII, which is also cleaved following the induction
of apoptosis [26,27]. In contrast to eIF4GI, which has two
caspase-3 cleavage sites [23,25,26], eIF4GII is postulated to
be cleaved by caspase-3 at ¢ve distinct sites [27]. To address
this possibility, extracts from wild-type cells subjected to dif-
ferent treatments were resolved on the same polyacrylamide
gel, which was then cut into strips to facilitate analysis of the
integrity of eIF4GI and eIF4GII (Fig. 2C). Using anti-peptide
antiserum speci¢c to the C-terminus of eIF4GII, these data
show that eIF4GII is cleaved following treatment of these
cells with MG132 (lane 5 vs. lane 4). Due to the low titre of
this antiserum, it was not possible to further identify the
cleavage fragments of eIF4GII. However, although these frag-
ments generated with MG132 showed some similarity to those
observed with anti-Fas treatment of cells (e.g. p140, p28; lane
Fig. 1. The proteasome inhibitor MG132 decreases cell viability, activates caspase-like proteases and invokes the cleavage of eIF4GI. Panel A:
Jurkat cells (5U106 cells in 5 ml) were incubated in the absence or presence of 2.5 Wg/ml MG132 for the times indicated. Cell viability was esti-
mated by trypan blue exclusion and the presented data are the means and S.D. (bars) of three separate experiments. Open symbols, wild-type
cells ; closed symbols, caspase-8 mutant cells. Panel B: Wild-type Jurkat cells (lanes 1^5) or caspase-8 mutant cells (lanes 6^10) were pre-incu-
bated for 60 min in the absence (lanes 1, 2, 4, 6, 7, 9) or presence of 50 WM zVAD.fmk (lanes 3, 5, 8, 10), prior to incubation with 2.5 Wg/ml
MG132 (lanes 2, 3, 7, 8) or 250 ng/ml anti-Fas antiserum (lanes 4, 5, 9, 10) for 8 h. Caspase-3-like activity was determined with the £uorogenic
substrate AC-DEVD-AMC and caspase-8-like activity with AC-IETD-AMC, as described in Section 2. The presented data are the means and
S.D. (bars) of two separate experiments, each performed in triplicate. Panel C: Wild-type (lanes 1 and 2) or caspase-8 mutant Jurkat cells
(lanes 3^6) were pre-incubated for 60 min in the absence (lanes 1^5) or presence of 50 WM zVAD.fmk (lane 6), prior to incubation without
(lanes 1,3) or with 2.5 Wg/ml MG132 (lanes 2, 4, 5, 6) for 8 h. Cell extracts were prepared and equal amounts of protein (7.5 Wg) were resolved
by SDS^PAGE. The integrity of eIF4GI was visualised by immunoblotting using antiserum W speci¢c to the middle domain of eIF4G (Fig.
2B) and the p85 cleavage fragment of PARP was visualised using commercial antiserum (Promega, UK). Results are representative of those ob-
tained in three separate experiments. Panel D: Jurkat cells (5U106 cells in 5 ml) were incubated in the absence or presence of the indicated
concentrations of MG132 for 20 h. Cell viability was estimated by trypan blue exclusion and the presented data are the means and S.D. (bars)
of three separate experiments. Open symbols, wild-type cells; closed symbols, caspase-8 mutant cells. Lower: Extracts were prepared from the
cultures and the integrity of eIF4GI was visualised by immunoblotting using antiserum W. Results are representative of those obtained in three
separate experiments.
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8 vs. lane 5), they were distinct from those observed with anti-
eIF4GI antiserum (lanes 1 and 2). Similar results were ob-
tained with the caspase-8 mutant cells and with both cell lines
following their incubation with lactacystin (data not shown).
This makes it unlikely that the M1 fragment is derived from
the C-terminal region of eIF4GII. This region of eIF4GII was
presumably processed into smaller fragments not resolved by
this gel system. This supposition is con¢rmed by the fact that
the only possible C-terminal immunoreactive fragments of
eIF4GII of the correct molecular weight to correspond to
the M1 fragment (48C, 58C; [27]), are not observed following
these treatments (lanes 4 and 6). In contrast, the p28 cleavage
fragment of eIF4GII [27] is clearly observed with MG132
(lane 5), anti-Fas antiserum (lane 8) and lactacystin (data
not shown).
3.2. Immunosuppressive drugs promote the cleavage of eIF4G
Previously, we have shown that although the immunosup-
pressive macrolide, rapamycin, promotes the destruction of
eIF4G in yeast [49], it does not induce the degradation of
eIF4GI in B or T cells [20,22]. As FTY720 and CsA have
been shown to induce apoptosis and activate stress kinases
in numerous cell types [37^41,50], we have investigated
whether they can promote the proteolysis of eIF4G in T cells.
Incubation of wild-type Jurkat T cells with CsA for 2^4 h
results in the cleavage of eIF4GI (Fig. 3A, lanes 1^4) and
eIF4GII (data not shown), promoting a loss in cell viability
(Fig. 3B). Similarly, FTY720 also promotes the cleavage of
eIF4GI (Fig. 2C, lane 3 vs. lane 1; Fig. 3A, lanes 5^8), eIF4-
GII (Fig. 2C, lane 6 vs. lane 4) and decreased viability in both
cell lines (Fig. 3B). In addition, these treatments result in the
cleavage of PARP, activation of caspase-like proteases, the
activation of p38 and JNK stress kinases, a 1.8-fold increase
in eIF2K phosphorylation and a drastic reduction in the rate
of protein synthesis (data not shown). In contrast to MG132
and lactacystin (Fig. 2), proteolysis of eIF4GI in response to
FTY720 or CsA does not result in the production of M-FAG
or C-FAG. As with MG132, the predominant fragment of
eIF4GI generated (M1) is recognised by antiserum W (Fig.
2A) but not with antiserum E (data not shown). As FTY720
and CsA also promote the proteolysis of eIF4GII in both cell
lines (Fig. 2C and data not shown), these data suggest that
caspase-8 activity is not required for cleavage of eIF4GI or
eIF4GII in response to immunosuppressants.
To determine whether the novel 50 kDa (M1) fragment of
eIF4GI contains the eIF4E-binding site, eIF4E and associated
proteins were recovered from extracts using m7GTP-Sephar-
ose. As shown in Fig. 3C, M-FAG retains the ability to asso-
ciate with eIF4E (lane 3 vs. lane 1). This is in agreement with
our previous studies [25]. However, the M1 fragment derived
from FT720-treated cells, which contains the central domain
of eIF4G (and thereby recognised by antiserum W) is not
recovered in the eluate (lane 4 vs. lane 2). Similar results
were obtained with extracts from MG132 and CsA-treated
cells (data not shown). Together with the lack of immunore-
activity with antiserum B, these data indicate that the 50 kDa
fragment of eIF4GI lacks the eIF4E-binding site.
3.3. Caspase and calpain inhibitors do not protect eIF4GI from
cleavage induced by CsA and FTY720
To determine whether the cleavage of eIF4GI following
immunosuppressant treatment requires caspase or calpain ac-
Fig. 2. MG132 and lactacystin promote the cleavage of eIF4GI and
eIF4GII into discrete fragments. Panel A: Wild-type (lanes 1^3 and
7^9) or caspase-8 mutant Jurkat cells (lanes 4^6 and 10^12; 5U106
cells in 5 ml) were incubated in the absence (lanes 1, 4, 7, 10) or
presence of 10 Wg/ml MG132 (lanes 2, 5, 8, 11) or 20 WM lactacys-
tin (lanes 3, 6, 9, 12) for 20 h. Equal amounts of protein (7.5 Wg)
were resolved by SDS^PAGE and the integrity of eIF4GI was vi-
sualised by immunoblotting using antiserum W (to the middle do-
main (left panel)) or antiserum E (to the C-terminus of eIF4GI
(right panel)). The migration of intact eIF4G, the M-FAG and C-
FAG cleavage products and the novel cleavage fragment of eIF4G
(M1) are indicated, and molecular weight markers are shown on the
left. Results are representative of those obtained in ¢ve separate ex-
periments. Panel B: Diagrammatic representation of eIF4GI, show-
ing sites of cleavage by caspase-3 (C-3; [25,26]), location of peptide
sequences used to generate antiserum used in these studies (B, W,
E) and sites of interaction with PABP, eIF4E, eIF4A, eIF3 and
Mnk1 (see Section 1 for details). Panel C: Jurkat cells (5U106 cells
in 5 ml) were incubated in the absence (lanes 1, 4, 7) or presence of
250 ng/ml anti-Fas antiserum (lane 8), 10 Wg/ml MG132 (lanes 2
and 5), or 25 WM FTY720 (lanes 3 and 6) for 6 h. Equal amounts
of protein (7.5 Wg) were resolved by SDS^PAGE and the integrity
of eIF4G was visualised by immunoblotting (lanes 1^3), eIF4GI
(antiserum W; lanes 4^8), antiserum speci¢c to the C-terminus of
eIF4GII [7]. The migration of intact eIF4G, the M-FAG and M1
cleavage fragments of eIF4GI are indicated on the left and those
speci¢c to eIF4GII (p140, p28; [27]) on the right.
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tivity, wild-type and caspase-8 mutant cells were pre-incu-
bated in the absence or presence of zVAD.fmk or ALLN
(MG101; calpain inhibitor II) prior to exposure to anti-Fas
antiserum, CsA or FTY720 (Fig. 4). Under these conditions,
ALLN alone does not in£uence the integrity of eIF4GI (data
not shown). In wild-type cells, anti-Fas antiserum promotes
the appearance of M-FAG with little change in the levels of
the M1 fragment (Fig. 4A, upper panel lane 2 vs. lane 1). The
cleavage of eIF4GI is insensitive to ALLN (lane 3 vs. lane 2)
but sensitive to zVAD.fmk (lane 4 vs. lane 2). Similarly, the
cleavage of eIF4GI in wild-type cells in response to either CsA
or FTY720 is insensitive to ALLN (lane 6 vs. lane 5 and lane
9 vs. lane 8, respectively). However, under these conditions,
the generation of the novel M1 fragment of eIF4GI is insen-
sitive to zVAD.fmk (lane 7 vs. lane 5 and lane 10 vs. lane 8).
In agreement with previous data, anti-Fas treatment of the
caspase-8 mutant cells does not induce cleavage of eIF4GI
(lower panel, lanes 1^4). However, as with the wild-type cells,
cleavage of eIF4GI in response to either CsA (lanes 5^7) or
FTY720 (lanes 8^10) is refractory to pre-treatment of cells
with ALLN or zVAD.fmk. These data suggest that activation
of caspase-8 or calpains are not required for the cleavage of
eIF4GI in response to immunosuppressants in vivo.
Throughout this study, it has been clear that a low level of
the M1 cleavage fragment observed with proteasome inhibi-
tors and immunosuppressants was present in untreated cells
(Fig. 2). To gain insight into the relationship of this fragment
to M-FAG, cells were incubated with anti-Fas antiserum for
longer periods of time. At extended times of exposure of wild-
type cells to anti-Fas antiserum, M-FAG is further processed
into a fragment which co-migrates with that induced by CsA
(Fig. 4B, lane 3 vs. lane 4). These data suggest that the novel
fragment of eIF4G observed with proteasome inhibitors and
immunosuppressive drugs is also generated at later times dur-
ing anti-Fas-mediated apoptosis.
4. Discussion
Stimulation of the Fas/CD95 receptor results in apoptosis
and the activation of stress kinases [21], the proteolysis of
eIF4GI and a severe, but incomplete inhibition of protein
synthesis [20^23,25,26]. We now show that the induction of
apoptosis following inhibition of the 26S proteasome with
MG312 or the 20S proteasome with lactacystin promotes
the cleavage of eIF4GI and eIF4GII in a caspase-8-indepen-
dent manner (Figs. 1 and 2). The sensitivity of this response to
zVAD.fmk (Fig. 1C) indicates the involvement of caspase-like
activities, which function downstream of caspase-8. An ideal
candidate would be caspase-3, which is strongly activated in
both cell lines in response to MG132 (Fig. 1B), and which has
been shown to be both necessary and su⁄cient for the cleav-
age of eIF4G in vitro and in vivo [23,26,28]. These ¢ndings
Fig. 3. CsA and FTY720 promote the caspase-8-independent cleavage of eIF4GI and eIF4GII. Panel A: Jurkat cells (5U106 cells in 5 ml)
were incubated in the presence of CsA (12.5 WM) or 25 WM FTY720 for the times indicated. Extracts were prepared and the integrity of eIF4-
GI was visualised by immunoblotting with antiserum W. Results are from a single experiment, but are representative of those obtained on three
separate occasions. Panel B: Wild-type (open symbols) or caspase-8 mutant cells (closed symbols; 5U106 cells in 5 ml) were incubated in the
absence (lanes 1, 7) or presence of the following concentrations of immunosuppressants for the times indicated; lane 2, 3.12 WM CsA; lane 3,
6.25 WM CsA; lane 4, 12.5 WM CsA; lane 5, 25 WM CsA; lane 6, 50 WM CsA; lane 8, 1WM FTY720; lane 9, 5WM FTY720; lane 10, 10WM
FTY720; lane 11, 25 WM FTY720; lane 12, 50 WM FTY720. Cell viability was estimated by trypan blue exclusion and the presented data are
the means and S.D. (bars) of three separate experiments. Panel C: Extracts were prepared from cells incubated with anti-Fas antiserum (lanes
1, 3) or FTY720 (lanes 2, 4) for 4 h were either not fractionated (lanes 1, 2), or eIF4E and associated factors were isolated by m7GTP-Sephar-
ose chromatography. Recovered proteins were resolved by SDS^PAGE and eIF4GI, and its cleavage products were visualised by immunoblot-
ting. The migration of eIF4G, p120, M-FAG and the novel cleavage fragment (M1) are indicated on the right with the molecular weight
markers on the left. Results are representative of those obtained in three separate experiments.
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are also consistent with reports that MG132 will activate cas-
pase-3 in HL-60 cells [51] and cortical neurones [35], and
activates caspases-2,3,7,8 and 9 in glioma cells [36]. Further-
more, the latter study also showed that caspase-8 cleavage is
dispensable for MG132-induced apoptosis [36].
Immunosuppressants such as FTY720 and CsA also acti-
vate stress kinases (data not shown) and induce the cleavage
of both eIF4GI and eIF4GII (Figs. 2 and 3). Activation of
caspase-8 was also not required for this e¡ect, in agreement
with the report that FTY720 is able to induce apoptosis in
splenocytes isolated from Fas-knockout mice [52]. Consistent
with its biological e¡ects, FTY720 induces a drastic decrease
in levels of T lymphocytes in the blood [40,42], possibly re-
£ecting activation of caspase activity as a consequence of
cytochrome c release from mitochondria [41,53]. In contrast
to the results with MG132, cleavage of eIF4GI in both wild-
type and caspase-8 mutant cells in response to FTY720 and
CsA was insensitive to zVAD.fmk and ALLN (Fig. 4). These
data suggest that cellular proteases other than caspases and
calpains can also play a role in the degradation of eIF4GI.
Further work will be needed to identify the proteases respon-
sible for cleavage of eIF4GI in response to these immunosup-
pressants.
The data presented here indicate that MG132, lactacystin,
FTY720 and CsA promote the caspase-8-independent cleav-
age of eIF4GI to yield a novel 50 kDa immunoreactive frag-
ment (M1) which is not accumulated at early times during
Fas-induced apoptosis. However, it is present at low levels
in the Jurkat cell population (Fig. 2A), possibly re£ecting
the presence of apoptotic cells in the cultures [48]. Prolonged
exposure of wild-type cells to anti-Fas antiserum promoted
the conversion of M-FAG to this novel fragment of eIF4GI
(Fig. 4B). Studies with anti-peptide antisera speci¢c to distinct
regions of eIF4GI (Fig. 2B), in conjunction with the lack of
recovery of the FTY720-induced product on m7GTP-Sephar-
ose (Fig. 3C), indicate that it does not contain the extreme
N- or C-termini or the eIF4E-binding site. As such, it is pre-
sumed that the 50 kDa fragment would not function in re-
cruiting capped mRNA to the ribosome, but may function in
recruitment of IRES-containing mRNAs at later times during
apoptosis [23]. The lack of detection of the M1 fragment with
antiserum speci¢c to the C-terminus of eIF4GII con¢rmed
that it was most likely derived from eIF4GI (Fig. 2C). Fur-
thermore, eIF4GII is proteolysed into ¢ve or more fragments
at later times during cisplatin-induced apoptosis, destroying
the core central domain, which may contribute to the inhibi-
tion of protein synthesis observed during apoptosis [27].
We have postulated that the accumulation of the caspase-
generated eIF4GI cleavage fragments may directly in£uence
mRNA translation rates in vivo (reviewed in [23]). eIF4GI-
derived M-FAG may have a direct role in the translation of
speci¢c cellular mRNAs during apoptosis under conditions
where the interaction between the 5P and 3P ends of the
mRNA has been disrupted. Indeed, M-FAG occurs in both
ribosome-bound and soluble forms, retains the ability to as-
sociate with eIF4E and eIF4A [25,26], and thus is able to
recruit all the necessary factors for basal translation and to
interact with mRNA [3,10,54]. As such, M-FAG may still
support cap-dependent and/or cap-independent translation,
albeit at a low rate, during apoptosis [23,55]. It is interesting
to note that MG132 has been reported to increase the expres-
sion of stress-related proteins such as hsp27 and hsp70 [31], as
Fig. 4. eIF4GI is processed by a caspase- and calpain-independent
process in response to CsA and FTY720. Panel A: Wild-type (upper
panel) or caspase-8 mutant (lower panel) Jurkat cells (5U106 cells
in 5 ml) were pre-incubated in the absence or presence of 50 WM
zVAD.fmk or 10 Wg/ml ALLN, prior to incubation for 2 h in the
presence of 250 ng/ml anti-Fas antiserum (lanes 1^4), 1 h with 12.5
WM CsA (lanes 5^7) or 2 h with 25 WM FTY720, as indicated. Ex-
tracts were prepared, equal amounts of protein (7.5 Wg) were re-
solved by SDS^PAGE, and the integrity of eIF4G was visualised by
immunoblotting using antiserum W speci¢c for the central domain
of eIF4GI. The migration of intact eIF4G, M-FAG and the novel
cleavage fragment of eIF4G (M1) are indicated on the right and
molecular weight markers are shown on the left. Results are repre-
sentative of those obtained in four experiments. Panel B: Jurkat
cells (5U106 cells in 5 ml) were incubated in the absence (lane 1) or
presence of 250 ng/ml anti-Fas antiserum (lanes 2 and 3) or 12.5
WM CsA (lane 4) for the times indicated. Extracts were prepared
and the integrity of eIF4GI was visualised by immunoblotting as in
panel A. Results are representative of those obtained in three sepa-
rate experiments.
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well as the over-expression of transcriptional regulators
ATF3, GADD153 and MAD1 [56]. Further work will be
needed to address the potential role of the fragments of eIF4-
GI in controlling the level of gene products involved in pro-
liferation and the cellular stress response.
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